| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184702 | Gynecologic Oncology | 2016 | 5 Pages |
Abstract
Following â¥Â 3 prior lines of chemotherapy, olaparib 400 mg bid (capsule form) monotherapy demonstrated notable antitumor activity in patients with gBRCA1/2m advanced ovarian cancer. No new safety signals were identified.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Susan M. Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M. Stemmer, Ayala Hubert, Ora Rosengarten, Niklas Loman, Jane D. Robertson,